NBY: Summary for NOVABAY PHARMACEUTCL - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Monday, November 23, 2009, 7:53am EST - Canadian Markets open in 1 hour and 37 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

NovaBay Pharmaceuticals, Inc. (NBY)

On Nov 20: 1.96 USD 0.00 (0.00%)

MORE ON NBY

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

NOVABAY PHARMACEUTCL (AMEX:NBY) Delayed quote data

Last Trade:	1.96 USD
Trade Time:	Nov 20
Change:	0.00 (0.00%)
Prev Close:	1.96
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	8.00

Day's Range:	N/A - N/A
52wk Range:	1.00 - 3.24
Volume:	0
Avg Vol (3m):	40,559.1
Market Cap:	45.58M
P/E (ttm):	N/A
EPS (ttm):	-0.32
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Free Annual Reports

Add NBY to Portfolio

Download Data

HEADLINES

•	NOVABAY PHARMACEUTICALS, INC. Financials
	EDGAR Online Financials (Tue, Nov 17)

•	New Star Analyst Rankings for NOVABAY PHARMACEUTCL
	StarMine (Mon, Nov 16)

•	NovaBay Pharmaceuticals Reports Third Quarter Financials and Provides Update on Pipeline of Anti-Infective Compounds
	Marketwire (Fri, Nov 13)

•	NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Nov 12)

•	NovaBay hires chief scientific officer
	at bizjournals.com (Mon, Oct 19)

•	NovaBay closes $2.45 million stock offering
	AP (Wed, Aug 26)

•	NovaBay Pharmaceuticals Announces the Closing of Its $2.45 Million Registered Direct Offering of Common Stock and Warrants
	Marketwire (Wed, Aug 26)

•	NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
	EDGAR Online (Fri, Aug 21)

•	NovaBay Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering of Common Stock and Warrants
	Marketwire (Fri, Aug 21)

•	NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Fri, Aug 14)

More Headlines for NBY...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

NovaBay Pharmaceuticals, Inc. focuses on the development of product candidates targeting the treatment or prevention of a range of infections in hospital and non-hospital environments.

Full Company Profile

Add to Portfolio

Email to a Friend

•